These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 33477089

  • 1. Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
    Gibson D.
    J Inorg Biochem; 2021 Apr; 217():111353. PubMed ID: 33477089
    [Abstract] [Full Text] [Related]

  • 2. Multi-action Pt(IV) anticancer agents; do we understand how they work?
    Gibson D.
    J Inorg Biochem; 2019 Feb; 191():77-84. PubMed ID: 30471522
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Structure-Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands.
    Fronik P, Poetsch I, Kastner A, Mendrina T, Hager S, Hohenwallner K, Schueffl H, Herndler-Brandstetter D, Koellensperger G, Rampler E, Kopecka J, Riganti C, Berger W, Keppler BK, Heffeter P, Kowol CR.
    J Med Chem; 2021 Aug 26; 64(16):12132-12151. PubMed ID: 34403254
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.
    Chen H, Wang X, Gou S.
    J Inorg Biochem; 2019 Apr 26; 193():133-142. PubMed ID: 30731264
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
    Wang Z, Xu Z, Zhu G.
    Angew Chem Int Ed Engl; 2016 Dec 12; 55(50):15564-15568. PubMed ID: 27736029
    [Abstract] [Full Text] [Related]

  • 12. A Multi-action and Multi-target RuII -PtIV Conjugate Combining Cancer-Activated Chemotherapy and Photodynamic Therapy to Overcome Drug Resistant Cancers.
    Karges J, Yempala T, Tharaud M, Gibson D, Gasser G.
    Angew Chem Int Ed Engl; 2020 Apr 27; 59(18):7069-7075. PubMed ID: 32017379
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Targeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrate.
    Qiao X, Gao YY, Zheng LX, Ding XJ, Xu LW, Hu JJ, Gao WZ, Xu JY.
    Eur J Med Chem; 2021 Nov 05; 223():113730. PubMed ID: 34388483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.